featured
news articles

Total number of categories

Total number of articles

Market/Novel Tech

Spark Therapeutics (NASDAQ: ONCE) confirms that a definitive agreement will merge with Roche

Spark Therapeutics Inc,. has  reported that a definitive merger agreement with Roche to acquire Spark at a price of $114.50 per share in an all-cash transaction. As a result, Spark will have the value of approximately $4.8 billion on a fully diluted basis, inclusive of ~$500 million of projected net cash. The per share price […]

Read full story
Featured

***EURETINA launch the Retinal Medicine Clinical Research Funding Call***

The 2019 EURETINA Clinical Research Awards have initiated a new funding research Call to support and encourage independent clinical research in the field of retinal medicine. Clinical research, as proposed by clinician or non-clinician researchers, may conduct several types of clinical research, such as observational research studies, register studies (patient or disease registry), natural history […]

Read full story
Research

Study suggests that transferrin supplementation may be used as an adjunctive therapy to surgery for patients with retinal degeneration

A Paris-based research report suggests that transferrin, the iron-binding serum protein, could be useful to help to treat patients with retinal detachment (RD).  Human studies indicate that ocular fluids from patients with rhegmatogenous retinal detachment (RRD) shows that iron increases with detachment duration and correlates with poor visual recovery.  While there is clear progress made […]

Read full story
Introduction

March 15th, 2019: “EURETINA-Brief”© Issue No. 188

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the March 15th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story
Market/Novel Tech

Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10

Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the exercise of an Allergan option to develop and commercialize “EDIT-101” – a CRISPR-based technology for the treatment of Leber Congenital Amaurosis type 10 (LCA10).  CRISPR (an acronym for “clustered regularly […]

Read full story
Featured

***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***

EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH), valued at up to €2 million.  The Research Call seeks proposals from suitably qualified clinical investigators to address the current clinical uncertainty in respect of the medical management of sub-macular […]

Read full story

Latest News

Book Review